Our data suggest re-establishment of CXCL12 expression in colorectal carcinomas potentially serves as a target to sensitize these cells to chemotherapies while limiting metastatic progression by modulating levels of Bcl-2 family members. The gene discussed is BCL2; the disease is colorectal carcinoma.